- Home
- PHIO vs CVKD Comparison
PHIO vs CVKD Comparison
Compare PHIO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHIO | CVKD |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 19.0M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PHIO | CVKD |
|---|---|---|
| Price | $1.19 | $8.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.67 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 7.1M | 50.2K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $4.91 |
| 52 Week High | $4.19 | $20.39 |
Technical Indicators
Market Signals| Indicator | PHIO | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 57.50 |
| Support Level | $1.03 | $6.64 |
| Resistance Level | $1.21 | $8.79 |
| Average True Range (ATR) | 0.12 | 0.73 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 27.91 | 78.52 |
Price Performance
Historical ComparisonAbout PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.